Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects-Reference-Cited by-同舟云学术

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

Published:2018-11 Issue:11 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rodvold Keith A.¹,Gotfried Mark H.¹²,Isaacs Robin D.³,O'Donnell John P.³,Stone Emily³

Affiliation:

1. University of Illinois at Chicago, Chicago, Illinois, USA

2. Pulmonary Associates, PA, Phoenix, Arizona, USA

3. Entasis Therapeutics, Inc., Waltham, Massachusetts, USA

Abstract

ETX2514 is a novel β-lactamase inhibitor that broadly inhibits Ambler class A, C, and D β-lactamases. ETX2514 combined with sulbactam (SUL) in vitro restores sulbactam activity against Acinetobacter baumannii .

Funder

Entasis Therapeutics, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01089-18

Reference37 articles.

1. Acinetobacter Infection

2. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

3. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

4. Secular trends inAcinetobacter baumanniiresistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study

5. Emergence of antimicrobial resistance among Acinetobacter species

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex;Expert Review of Anti-infective Therapy;2024-09-08

2. Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review;Infectious Disorders - Drug Targets;2024-09

3. Novel Antibiotics for Gram-Negative Nosocomial Pneumonia;Antibiotics;2024-07-05

4. Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence;Antibiotics;2024-05-29

5. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece;Journal of Antimicrobial Chemotherapy;2024-03-19